MXPA06005547A - Composiciones farmaceuticas para el tratamiento de disfuncion, enfermedad o trastorno renal, en particular, en pacientes diabeticos. - Google Patents

Composiciones farmaceuticas para el tratamiento de disfuncion, enfermedad o trastorno renal, en particular, en pacientes diabeticos.

Info

Publication number
MXPA06005547A
MXPA06005547A MXPA06005547A MXPA06005547A MXPA06005547A MX PA06005547 A MXPA06005547 A MX PA06005547A MX PA06005547 A MXPA06005547 A MX PA06005547A MX PA06005547 A MXPA06005547 A MX PA06005547A MX PA06005547 A MXPA06005547 A MX PA06005547A
Authority
MX
Mexico
Prior art keywords
group
patients
treatment
disease
formula
Prior art date
Application number
MXPA06005547A
Other languages
English (en)
Spanish (es)
Inventor
Berthold Hocher
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of MXPA06005547A publication Critical patent/MXPA06005547A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA06005547A 2003-11-18 2004-11-15 Composiciones farmaceuticas para el tratamiento de disfuncion, enfermedad o trastorno renal, en particular, en pacientes diabeticos. MXPA06005547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03104264 2003-11-18
PCT/EP2004/052963 WO2005049035A1 (en) 2003-11-18 2004-11-15 Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients

Publications (1)

Publication Number Publication Date
MXPA06005547A true MXPA06005547A (es) 2006-08-17

Family

ID=34610099

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06005547A MXPA06005547A (es) 2003-11-18 2004-11-15 Composiciones farmaceuticas para el tratamiento de disfuncion, enfermedad o trastorno renal, en particular, en pacientes diabeticos.

Country Status (15)

Country Link
US (1) US7273860B2 (cg-RX-API-DMAC10.html)
EP (1) EP1687006B1 (cg-RX-API-DMAC10.html)
JP (1) JP4824573B2 (cg-RX-API-DMAC10.html)
CN (1) CN100566719C (cg-RX-API-DMAC10.html)
AR (1) AR046454A1 (cg-RX-API-DMAC10.html)
AT (1) ATE378053T1 (cg-RX-API-DMAC10.html)
AU (1) AU2004290925B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0416706A (cg-RX-API-DMAC10.html)
CA (1) CA2545802A1 (cg-RX-API-DMAC10.html)
DE (1) DE602004010172T2 (cg-RX-API-DMAC10.html)
ES (1) ES2297536T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA06005547A (cg-RX-API-DMAC10.html)
PL (1) PL1687006T3 (cg-RX-API-DMAC10.html)
TW (1) TWI344366B (cg-RX-API-DMAC10.html)
WO (1) WO2005049035A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036610A1 (en) * 1999-11-19 2001-05-25 Solvay Pharmaceuticals B.V. Human enzymes of the metalloprotease family
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
US20060159748A1 (en) * 2004-12-23 2006-07-20 Rajesh Jain Oral immediate release formulation of a poorly water-soluble active substance
US11844803B2 (en) * 2017-12-11 2023-12-19 Aetas Pharma Co., Ltd. Renal dysfunction improving drug comprising optical isomer of 1,4-benzothiazepine-1-oxide derivative
PL424453A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Sposoby zmniejszania szkodliwego działania niedoboru perfuzji narządów miąższowych przez inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP)
ES2899200T3 (es) * 2018-06-22 2022-03-10 Synact Pharma Aps Tratamiento de proteinuria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254032A3 (en) * 1986-06-20 1990-09-05 Schering Corporation Neutral metalloendopeptidase inhibitors in the treatment of hypertension
DE19510566A1 (de) 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
IL162645A0 (en) * 2002-01-16 2005-11-20 Solvay Pharm Bv solid salts benzazepine compounds and their use inthe preparation of pharmaceuticals compounds
TW200306799A (en) * 2002-05-17 2003-12-01 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
CN100566719C (zh) 2009-12-09
EP1687006B1 (en) 2007-11-14
CA2545802A1 (en) 2005-06-02
BRPI0416706A (pt) 2007-01-16
US7273860B2 (en) 2007-09-25
DE602004010172T2 (de) 2008-09-11
AR046454A1 (es) 2005-12-07
TWI344366B (en) 2011-07-01
US20050137183A1 (en) 2005-06-23
AU2004290925A1 (en) 2005-06-02
ES2297536T3 (es) 2008-05-01
WO2005049035A1 (en) 2005-06-02
TW200526228A (en) 2005-08-16
PL1687006T3 (pl) 2008-01-31
ATE378053T1 (de) 2007-11-15
DE602004010172D1 (de) 2007-12-27
AU2004290925B2 (en) 2010-07-01
JP4824573B2 (ja) 2011-11-30
HK1097762A1 (zh) 2007-07-06
CN1878557A (zh) 2006-12-13
EP1687006A1 (en) 2006-08-09
JP2007511582A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
EP2968245B1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
US6693129B2 (en) Compositions and methods for lowering plasma lipoprotein(A) and risk factors of cardiovascular diseases
US10441560B2 (en) Compositions and methods for treating non-alcoholic steatohepatitis
ES2201822T3 (es) Combinaciones de inhibididores de la proteina de transferencia de ester de colesterilo y de derivados de acido nicotinico para indicaciones cardiovasculares.
JP2002533415A (ja) 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびニコチン酸誘導体の組み合わせ
AU2002211452A1 (en) Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases
CZ20012340A3 (cs) Kombinace inhibitorů transportu kyčelní ľlučové kyseliny a proteinových inhibitorů cholesteryl-esterového přenosu pro kardiovaskulární indikace
JP2002533413A (ja) 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびフィブリン酸誘導体の組み合わせ
WO2012068539A1 (en) Use and composition of quercetin-3'-o-sulfate for therapeutic treatment
EP1687006B1 (en) Pharmaceutical compositions for the treatment of renal dysfunction
RU2423692C2 (ru) Вещества для профилактики и лечения панкреатита
HK1097762B (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
US6323203B1 (en) Composition and method for treating diabetes
HK40056055A (en) Novel pharmaceutical composition
Russmann et al. Low membrane protein sulfhydrils but not glucose‐6‐phosphate dehydrogenase deficiency predict ribavirin‐induced hemolysis

Legal Events

Date Code Title Description
FG Grant or registration